These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10854137)

  • 41. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).
    Erlichman C; Moore M; Kerr IG; Wong B; Eisenhauer E; Zee B; Whitfield LR
    Cancer Res; 1991 Dec; 51(23 Pt 1):6317-22. PubMed ID: 1933893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
    Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
    Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
    Vogelzang NJ; Mani S; Schilsky RL; Ansari RH; Taber D; Rhinehart SN; Garcia JC; Meyer SC; Mick R; Brockstein BE; Stadler WM; Ratain MJ; Vokes EE
    Clin Cancer Res; 1998 Apr; 4(4):929-34. PubMed ID: 9563886
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells.
    Takatori T; Koizumi T; Tokui T; Mitsuhashi Y; Shiraishi A; Tsuruo T
    Cancer Chemother Pharmacol; 1995; 35(4):283-90. PubMed ID: 7828270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo.
    Tokui T; Maeda N; Kuroiwa C; Sasagawa K; Inoue T; Kawai K; Ikeda T; Komai T
    Pharm Res; 1995 Mar; 12(3):370-5. PubMed ID: 7617523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of stepwise and simultaneous estimations of population pharmacokinetics and pharmacodynamics of TS-943.
    Furuya A; Kato N; Jingu S; Akimoto M; Kasai O; Suwa T; Sato M; Ogata H
    Eur J Drug Metab Pharmacokinet; 2003; 28(3):191-9. PubMed ID: 14527092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
    Tolcher AW; Aylesworth C; Rizzo J; Izbicka E; Campbell E; Kuhn J; Weiss G; Von Hoff DD; Rowinsky EK
    Ann Oncol; 2000 Mar; 11(3):333-8. PubMed ID: 10811501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
    Graham MA; Bissett D; Setanoians A; Hamilton T; Kerr DJ; Henrar R; Kaye SB
    J Natl Cancer Inst; 1992 Apr; 84(7):494-500. PubMed ID: 1545439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I and pharmacokinetic study of rhizoxin.
    Bissett D; Graham MA; Setanoians A; Chadwick GA; Wilson P; Koier I; Henrar R; Schwartsmann G; Cassidy J; Kaye SB
    Cancer Res; 1992 May; 52(10):2894-8. PubMed ID: 1581905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and early clinical studies of selected new drugs.
    Kaye SB; Workman P; Graham MA; Cassidy J; Jodrell D
    Cancer Surv; 1993; 17():371-96. PubMed ID: 8137348
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
    Goh BC; Fleming GF; Janisch L; Vogelzang NJ; Stadler WM; Ratain MJ
    Cancer Chemother Pharmacol; 2000; 45(6):489-94. PubMed ID: 10854137
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.